Focused On-demand Library for Alkaline phosphatase, germ cell type

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.







Alternative names:

ALP-1; Alkaline phosphatase Nagao isozyme; Alkaline phosphatase, placental-like; Germ cell alkaline phosphatase; Placental alkaline phosphatase-like

Alternative UPACC:

P10696; A8KAF2; Q16727; Q53S81; Q96CM1


Alkaline phosphatase, germ cell type (P10696), known by alternative names such as ALP-1, Alkaline phosphatase Nagao isozyme, and Placental alkaline phosphatase-like, plays a crucial role in hydrolyzing various phosphate compounds. This enzyme's activity is pivotal in numerous biological processes, including bone mineralization and the breakdown of phosphate esters, which are vital for cellular energy and signaling.

Therapeutic significance:

Understanding the role of Alkaline phosphatase, germ cell type, could open doors to potential therapeutic strategies. Its ability to hydrolyze phosphate compounds suggests its involvement in key physiological pathways, offering a promising avenue for the development of treatments targeting metabolic and bone diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.